Recent submissions
Now showing items 121-140 of 889
-
Solitary fibrous tumor: molecular hallmarks and treatment for a rare sarcoma.
(FUTURE MEDICINE LTD, 2021-09-01)Solitary fibrous tumor (SFT) is a rare soft tissue sarcoma subtype which mainly affects adults in the fifth and sixth decades of life. Originally part of a spectrum of tumors called hemangiopericytomas, classification has ... -
Advances in the proteomic profiling of the matrisome and adhesome.
(TAYLOR & FRANCIS LTD, 2021-09-02)INTRODUCTION: The matrisome and adhesome comprise proteins that are found within or are associated with the extracellular matrix (ECM) and adhesion complexes, respectively. Interactions between cells and their microenvironment ... -
Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency.
(NATURE PORTFOLIO, 2021-11-08)PARP enzymes utilise NAD+ as a co-substrate for their enzymatic activity. Inhibition of PARP1 is synthetic lethal with defects in either BRCA1 or BRCA2. In order to assess whether other genes implicated in NAD+ metabolism ... -
Late recurrence in ER+ breast cancer - refining risk prediction beyond 5 years
(Institute of Cancer Research (University Of London), 2021-11-30)ER positive (ER+) breast cancer has the potential to recur many years following diagnosis. Predicting who is most at risk of recurrence and when this may occur is complex. Risk prediction incorporates clinical, pathological ... -
A study of the co-evolution of the genome and epigenome in colorectal cancer using multi-omics profiling
(Institute of Cancer Research (University Of London), 2021-11-30) -
Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial.
Purpose The VIT-0910 trial was conducted to evaluate efficacy and safety of the vincristine-irinotecan combination with and without temozolomide (VIT and VI, respectively) in relapsed or refractory rhabdomyosarcoma (RMS). ... -
Defining the role of SF3B1K700E mutations in ER+ breast cancer
(Institute of Cancer Research (University Of London), 2021-09-30)Mutations in SF3B1, a component of the RNA splicing machinery, underpin a number of aggressive cancers. Hotspot mutations in SF3B1 are present in around 3% of breast cancers, are enriched in oestrogen receptor positive ... -
Analysis of novel therapeutic options for adenoid cystic carcinoma of the salivary glands
(Institute of Cancer Research (University Of London), 2021-04-30)Adenoid cystic adenocarcinoma (ACC) of the salivary glands is characterised by slow growth, frequent metastasis and low survival rates. ACC is resistant to conventional chemotherapy and currently, no systemic agent has ... -
Next generation circulating tumour DNA detection and subclonality analysis for gastrointestinal cancer therapy personalisation
(Institute of Cancer Research (University Of London), 2021-05-31)Background: Gastrointestinal cancers are associated with poor outcomes as many patients present with advanced disease. Intratumour heterogeneity (ITH) is a major barrier to predicting the evolution of cancers and successful ... -
Recent Advances in ALK2 Inhibitors.
(AMER CHEMICAL SOC, 2021-08-17)Activin receptor-like kinase-2 (ALK2) is a type I bone morphogenetic protein (BMP) receptor which has a role in biological processes that control the development of bone, heart, brain, and other tissue. Gain of function ... -
Quantitative Assessment and Prognostic Associations of the Immune Landscape in Ovarian Clear Cell Carcinoma.
(MDPI, 2021-07-30)Ovarian clear cell carcinoma (OCCC) is a rare subtype of epithelial ovarian cancer characterised by a high frequency of loss-of-function ARID1A mutations and a poor response to chemotherapy. Despite their generally low ... -
Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1-Mutant Diffuse Intrinsic Pontine Glioma.
(AMER ASSOC CANCER RESEARCH, 2022-02-01)Somatic mutations in ACVR1 are found in a quarter of children with diffuse intrinsic pontine glioma (DIPG), but there are no ACVR1 inhibitors licensed for the disease. Using an artificial intelligence-based platform to ... -
The evolving management of epithelioid sarcoma.
(2021-07-18) -
The molecular pathology of infant gliomas
(Institute of Cancer Research (University Of London), 2021-04-30)Infant high grade gliomas appear clinically distinct from their counterparts in older children, indicating that histopathologic grading may not accurately reflect the biology of these tumours. I have collected 241 cases ... -
Intratumor morphologic and transcriptomic heterogeneity in V600EBRAF-mutated metastatic colorectal adenocarcinomas.
(ELSEVIER, 2021-08-01)BACKGROUND: Intratumor heterogeneity (ITH) is described as the presence of various clones within one tumor, each with their own unique features in terms of morphology, inflammation, genetics or transcriptomics. Heterogeneity ... -
Genetics of high risk myeloma
(Institute of Cancer Research (University Of London), 2021-03-31)Despite significant progress in therapy in the last two decades, the outlook for multiple myeloma (MM) patients is still poor as the disease remains incurable and only 33% of patients survive for up to 10 years after ... -
JunD, not c-Jun, is the AP-1 transcription factor required for Ras-induced lung cancer.
(AMER SOC CLINICAL INVESTIGATION INC, 2021-07-08)The AP-1 transcription factor c-Jun is required for Ras-driven tumorigenesis in many tissues and is considered as a classical proto-oncogene. To determine the requirement for c-Jun in a mouse model of K-RasG12D-induced ... -
Pharmacotherapy for liposarcoma: current and emerging synthetic treatments.
(TAYLOR & FRANCIS LTD, 2021-04-21)Liposarcomas are rare tumors arising from adipocytic tissue and accounting for approximately 15-20% of all soft tissue sarcomas. Liposarcoma can be further classified into histopathological subtypes with variable ... -
Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium.
(LIPPINCOTT WILLIAMS & WILKINS, 2021-09-10)PURPOSE: Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood. Despite aggressive therapy, the 5-year survival rate for patients with metastatic or recurrent disease remains poor, and beyond PAX-FOXO1 fusion ...